KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
EC grants conditional marketing authorization based on the EFFISAYIL trial
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
Subscribe To Our Newsletter & Stay Updated
